CCOP, MBCCOP & Research Base
1 / 15

Mimi Passarello, M.B.A. NSABP, Pittsburgh, PA - PowerPoint PPT Presentation

  • Uploaded on

CCOP, MBCCOP & Research Base Principal Investigator and Administrator Meeting Breakout Session: Drug Distribution. Mimi Passarello, M.B.A. NSABP, Pittsburgh, PA. NSABP Trials – Resources for Protocol-Specific Drug Accountability. Protocol* Protocol-Related Documents Fact Sheet*

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about ' Mimi Passarello, M.B.A. NSABP, Pittsburgh, PA' - seth-mendez

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
CCOP, MBCCOP & Research BasePrincipal Investigator and Administrator MeetingBreakout Session: Drug Distribution

Mimi Passarello, M.B.A.

NSABP, Pittsburgh, PA

Nsabp trials resources for protocol specific drug accountability
NSABP Trials – Resources for Protocol-Specific Drug Accountability

  • Protocol*

  • Protocol-Related Documents

    • Fact Sheet*

    • Nurse/CRA Guidelines

What auditors review
What Auditors Review Accountability

Drug Accountability Record Form (DARF)

  • DARFs (or NCI-approved logs) are present for all investigational agents

  • Logs are completely and correctly filled out

  • Separate form for each agent / protocol / dosage form / dosage strength

  • Logs for all satellites

What auditors review con t
What Auditors Review Accountability(con’t)

Storage and Stability

  • Balance on the DARF matches the physical inventory and/or discrepancies are accounted for

  • All study drugs are stored securely in a separate, limited-access area (at appropriate temperatures)

  • Expired drugs are disposed of or returned

  • Unused drug on closed studies has been transferred properly to open protocols or has been returned

What auditors review con t1
What Auditors Review Accountability(con’t)

Tracking and Disposition

  • Shipping receipts, transfer forms and drug return forms for each drug are on file

  • Destruction records are on file

  • Able to follow drug from shipment to patient (including dates)

Nsabp pharmacy drug accountability audit results june 1 2006 may 31 2007
NSABP Pharmacy/Drug Accountability Audit Results AccountabilityJune 1, 2006 – May 31, 2007

Major drug accountability issues nsabp sees on audit
“Major” Drug Accountability Issues AccountabilityNSABP Sees on Audit

  • Use of commercial agent when agent is supplied

    • Patient / insurance charged in error

    • Cost to site

    • Do not replace commercial agent with investigational

  • Shipping of agents between sites

  • NCI logs not in use for PMB-supplied agents and/or use specified in protocol; particularly problematic for double-blind trials

  • No log for small offices

“Lesser” Drug Accountability Issues NSABP sees on Audit: Accountability

  • “Write-overs”, changes not initialed

  • Math errors corrected during audit

  • Late return of drug

  • Blanks, incomplete headings

Some nsabp protocols allow shipment to patient double blind tamoxifen
Some NSABP Protocols allow shipment to patient Accountability(double blind, tamoxifen)

  • Oral agents, stable at room temperature

  • Patients on long-term treatment

  • Intensive, frequent on-site follow-up not required

  • Patient-specific labeling on bottles

  • Controlled ordering through NSABP Biostatistical Center

Newer issues
Newer Issues Accountability

  • Double blind studies only – patient returns of IND agents are recorded on log

  • Master logs highly recommended by NSABP for double blind studies

Avoiding problems
Avoiding Problems Accountability

  • Conduct periodic audits of pharmacies

  • Communication with pharmacist regarding study-specific information

  • Read protocol and protocol-related documents

  • Avoid re-writing messy drug logs

Audit Program Accountability

CTMB Guidelines Presentation and Audit Deficiencies, provided by the Clinical

Trials Monitoring Branch 3/07

  • CTMB Audit Deficiency Examples

  • Guidelines for Monitoring of Clinical Trials for Cooperative


    Site Visit Audit News(01/11/2007)

    Audit Program Description (07/17/2007)

    Examples of Audit Deficiencies (06/19/2007)

    Sample of Notification Letter (Treatment) (07/17/2007)

    Sample of Notification Letter (Prevention) (07/17/2007)

    Sample of Final Report (Treatment)

    Sample of Final Report (Prevention)